Answers are grounded in this paper and cite their sources.
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory disorder characterized by persistent airflow limitation, chronic inflammation, and progressive respiratory impairment. Its clinical presentation and progression vary considerably among patients, creating challenges for diagnosis, treatment selection, and long-term disease control. Emerging evidence supports personalized approaches that address pulmonary and extrapulmonary disease characteristics. Aim: This review examines recent developments in COPD assessment and management, with particular emphasis on treatable traits, biological therapies, smoking cessation, pulmonary rehabilitation, oxygen therapy, and associated comorbidities. Methods: A narrative review approach was used to discuss evidence concerning COPD pathophysiology, diagnostic investigations, emerging therapeutic strategies, and multidisciplinary management. Particular attention was given to clinical trials investigating targeted biological agents and interventions addressing modifiable disease characteristics. Results: COPD assessment increasingly incorporates spirometry, imaging, inflammatory biomarkers, and functional investigations to identify disease phenotypes and support earlier diagnosis. The treatable traits approach provides a personalized framework for managing pulmonary, extrapulmonary, and behavioral factors, including its potential application in pre-COPD. Among biological therapies, dupilumab has demonstrated reductions in moderate or severe exacerbations and improvements in lung function among patients with elevated blood eosinophils. Evidence supporting IL-5 and TSLP pathway inhibitors remains inconsistent, while IL-33-targeted therapies require further investigation. Smoking cessation, pulmonary rehabilitation, and appropriate oxygen therapy remain essential management strategies. Cardiovascular disease, sleep-disordered breathing, obesity, and dysfunctional breathing also require systematic assessment because they influence clinical outcomes and disease burden. Conclusion: COPD management is evolving toward personalized, multidimensional care. Integrating early diagnosis, treatable traits, targeted therapies, lifestyle interventions, and comorbidity management may improve treatment selection and patient outcomes.
No takes yet. Share an insight, caveat, or question.
Ammash et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: